Cell-Free Circulating Mitochondrial DNA: A Potential Blood-Based Marker for Atrial Fibrillation

Atrial fibrillation (AF), the most common, progressive tachyarrhythmia is associated with serious complications, such as stroke and heart failure. Early recognition of AF, essential to prevent disease progression and therapy failure, is hampered by the lack of accurate diagnostic serum biomarkers to...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2020-05, Vol.9 (5), p.1159
Main Authors: Wiersma, Marit, van Marion, Denise M S, Bouman, Emma J, Li, Jin, Zhang, Deli, Ramos, Kennedy S, Lanters, Eva A H, de Groot, Natasja M S, Brundel, Bianca J J M
Format: Article
Language:English
Subjects:
Aged
Animals
atrial fibrillation
Atrial Fibrillation - blood
Atrial Fibrillation - genetics
Atrial Fibrillation - surgery
Bioluminescence
biomarker
Biomarkers
Biomarkers - blood
Cardiac arrhythmia
Cardiomyocytes
Cell Line
Cell-Free Nucleic Acids - blood
Chaperonin 60 - blood
Chaperonin 60 - metabolism
Congestive heart failure
Deoxyribonucleic acid
Diabetes
Digital imaging
DNA
DNA, Mitochondrial - blood
Female
Fibrillation
Heart failure
Humans
Inflammation
Laboratories
Male
Mice
Middle Aged
Mitochondria - metabolism
Mitochondria - pathology
Mitochondrial DNA
Morphology
Mortality
Patients
Peptides
Recurrence
Semiconductors
serum
Sex Characteristics
Sex differences
Stroke
Surgery
Tachyarrhythmia
Technological change
Thermal cycling
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atrial fibrillation (AF), the most common, progressive tachyarrhythmia is associated with serious complications, such as stroke and heart failure. Early recognition of AF, essential to prevent disease progression and therapy failure, is hampered by the lack of accurate diagnostic serum biomarkers to identify the AF stage. As we previously showed mitochondrial dysfunction to drive experimental and human AF, we evaluated whether cell-free circulating mitochondrial DNA (cfc-mtDNA) represents a potential serum marker. Therefore, the levels of two mtDNA genes, COX3 and ND1, were measured in 84 control patients (C), 59 patients undergoing cardiac surgery without a history of AF (SR), 100 paroxysmal (PAF), 116 persistent (PeAF), and 20 longstanding-persistent (LS-PeAF) AF patients undergoing either cardiac surgery or AF treatment (electrical cardioversion or pulmonary vein isolation). Cfc-mtDNA levels were significantly increased in PAF patients undergoing AF treatment, especially in males and patients with AF recurrence after AF treatment. In PeAF and LS-PeAF, cfc-mtDNA levels gradually decreased. Importantly, cfc-mtDNA in serum may originate from cardiomyocytes, as in vitro tachypaced cardiomyocytes release mtDNA in the medium. The findings suggest that cfc-mtDNA is associated with AF stage, especially in males, and with patients at risk for AF recurrence after treatment.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells9051159